



Prof Annegret Kuhn

An overview of projects approved by EADV's Project Proposal Review Committee for funding in 2012 and 2013

European Guidelines for Cutaneous Lupus Erythematosus

Project ref: 2013/007

Project proposer: Prof Annegret Kuhn

Lupus erythematosus is a complex and heterogeneous autoimmune disease, which shows many different clinical manifestations ranging from primary cutaneous lesions (cutaneous Lupus erythematosus, CLE) to severe systemic organ manifestations (systemic Lupus erythematosus, SLE).

In particular, patients with skin manifestations demonstrate a high disease burden and an impaired quality of life.

Due to the lack of standardised therapeutic procedures, the aim of this project was

the development of European Guidelines for the treatment of patients with CLE in cooperation with the European Academy of Dermatology and Venerology (EADV) and the European Dermatology Forum (EDF). To achieve a broad consensus on recommendations for therapeutic strategies in CLE, 15 experts from all over Europe were included on the Guidelines Sub-Committee.

At a consensus conference in July 2014, a draft of the guidelines for treatment of patients with CLE, prepared by all the experts, was discussed. Moreover,

a recommendation was defined and a consensus was achieved for each therapeutic option. The recommendations were validated according to the system developed by the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) and are included in the manuscript.

In addition to dermatology, the evidence-based guidelines also address other medical disciplines that diagnose and treat patients suffering from lupus erythematosus, such as rheumatology. ●



© Peter Pulkovits

Prof Annegret Kuhn

PPRC-supported projects

Feedback from some of the 2015 grant recipients

European Guidelines for Cutaneous Lupus Erythematosus

Part I: Treatment; Part II: Diagnosis and Monitoring

EADV/EDF Guideline Sub-Committee on Cutaneous Lupus Erythematosus

Lupus erythematosus is a complex and heterogeneous autoimmune disease, which shows many different clinical manifestations ranging from primary cutaneous lesions (cutaneous Lupus erythematosus, CLE) to severe systemic organ manifestations (systemic Lupus erythematosus, SLE). In particular, patients with skin manifestations demonstrate a high disease burden and an impaired quality of life. Due to the lack of standardised therapeutic procedures, the aim of the present project is the development of European Guidelines for the treatment of patients with CLE in cooperation with EADV and the European Dermatology Forum (EDF). In addition to dermatology, the consensus-based guidelines also address other medical disciplines that diagnose and treat patients suffering from lupus erythematosus, such as rheumatology.

To achieve a broad consensus on recommendations for therapeutic strategies in CLE, 15 experts from all over Europe are included in the guidelines sub-committee. All authors agreed to start with the development of "S2 Guidelines for Treatment of Cutaneous Lupus Erythematosus" (Part I) and to work on "Guidelines on Diagnosis/Monitoring" (Part II) in a second step. At a consensus conference in July 2014, a draft of Part I, the guidelines for treatment of patients with CLE, was discussed. For each treatment option, a consensus was achieved, a recommendation defined and included in a manuscript. The manuscript of the "S2 Guidelines for Treatment of Cutaneous Lupus Erythematosus" was written according to the instructions of the *Journal of the European Academy of*

Dermatology and Venereology (JEADV) and a treatment algorithm for CLE was defined in summer 2015. The "S2 Guidelines for Treatment of Cutaneous Lupus Erythematosus" was submitted to the EDF in January 2016 and is currently under revision.

In addition to the finalisation of Part I of the "S2 Treatment Guidelines", the development of Part II, the "S2 Guidelines for Diagnosis of Cutaneous Lupus Erythematosus" and the "S2 Guidelines for Monitoring of Cutaneous Lupus Erythematosus" was initiated and discussed at the 2nd Consensus Conference in November 2015. The first draft of Part II is currently in progress and will be finalised this year. ●